Efficacy and Safety of Newer Targeted Immunotherapy for Multiple Myeloma

Conclusion:Our study demonstrated that siltuximab combination regimens have shown excellent efficacy in NDMM pts compared to RRMM pts with an ORR of 88% vs. 46%. Similarly, better OS (88% vs. 81%) and mPFS (17 months vs. 8 months) were found in NDMM pts compared to RRMM pts. Neutropenia and thrombocytopenia were the major side effects reported with siltuximab. Pembrolizumab and tabalumab have shown moderate efficacy in RRMM pts with an ORR of 60%. However, isatuximab has shown mild efficacy in RRMM pts with an ORR of 24%. These drugs are well tolerated compared to siltuximab. Significant data in the literature are lacking and data from larger study population are needed.DisclosuresNo relevant conflicts of interest to declare.

Source: Blood - November 21, 2018 Category: Hematology Authors: Aslam, S., Riaz, R., Malik, M. N., Rafae, A., Faridi, W., Malik, S. U., Selene, I. I., Shah, Z., Sohail, C. S., Mahfooz, F., Samuel, S., Yasir, M., Anwer, F. Tags: 653. Myeloma: Therapy, excluding Transplantation Source Type: research